Helsinn And BridgeBio Ink Infigratinib Cancer Pact

Duo Will Co-develop And Commercialise FGFR1-3 inhibitor In Oncology

 
• By Sten Stovall
Helsinn Handshake
BridgeBio retains full rights to infigratinib for use in skeletal dysplasias • Source: Shutterstock

More from Deals

More from Business